Beactica Therapeutics announces the selection of BEA-17 as a preclinical candidate

Beactica Therapeutics AB, the Swedish precision oncology company, today announced the selection of BEA-17 as a preclinical candidate for its LSD1 programme aimed at finding new therapies for aggressive brain tumours and other life-threatening cancers. BEA-17 is a first-in-class small…